Isomorphic Labs seeks a $40 billion valuation before its first human trial
Alphabet's Isomorphic Labs is in funding talks at a $40 billion valuation. Crypto Briefing put its prior mark near $17.5 billion, so the ask more than doubles the price of a drug designer that has yet to dose a patient.
The Investor · Invest desk
What happened
- Crypto Briefing, citing an October 8 Bloomberg report, said the valuation would be at least $40 billion and could reach as much as $50 billion.
- The talks come five months after Isomorphic closed a $2.1 billion Series B that drew Thrive Capital, Alphabet and the UK Sovereign AI Fund.
- Eli Lilly, Novartis and Johnson & Johnson are partners, and the 2024 Lilly and Novartis deals carry more than $3 billion in combined potential milestones.
Why it matters
- Who has to decide decision Thrive Capital, which led the Series A and joined the Series B, has to decide whether to buy again at more than twice the mark that preceded these talks.
- Who's exposed exposure Investors who buy at $40 billion are underwriting the plan to start first-in-human trials by the end of 2026; a delay would leave them holding the highest mark with no human data.
- What it limits constraint Even if every Lilly and Novartis milestone paid out, the $3 billion-plus would equal roughly 7.5% of a $40 billion valuation, so most of the price has to come from Isomorphic's own pipeline.
Next story · Invest · 2d ago
Hassabis calls AI agent hacks 'early warning shots', says they could turn major within a couple of years without more security workConfirmed2 publishers
A $40 billion valuation is about 14.8 times the disclosed outside money Isomorphic has raised [17]. At the $50 billion top end, the multiple is about 18.5 [18]. Against the prior mark of roughly $17.5 billion, the lower figure adds $22.5 billion of paper value, a 2.3-fold step [19], in the five months since the Series B closed [4]. Round sizes are climbing too. The $2.1 billion Series B was 3.5 times the $600 million Series A raised 14 months earlier [20].
The asset being priced is software [8]. IsoDDE, the Isomorphic Drug Design Engine, builds on DeepMind's AlphaFold protein-structure technology [8], and the company has released no clinical data [9].
If the round closes at $40 billion or more, the figure becomes a price investors paid. For now the talks are preliminary [3]. A lower close, or none, would leave it as an ask. Semafor set the talks against fears that AI spending, on track to far exceed past investment booms, is building a bubble whose burst would bring "a far-reaching shock" [15]. A third outcome is a close at the top of the range, near 2.9 times the prior mark [21].
I think $40 billion is a poor comparable for other private AI drug-discovery companies, even if it closes. It prices Alphabet's majority ownership [12] and a chief executive, Demis Hassabis, who won a Nobel Prize and ran Google DeepMind [7]. Another startup cannot borrow either. Semafor's comparison set was DeepSeek, Moonshot and OpenAI, firms chasing billions to stay ahead in the global AI race [16]. The reports cite no other AI drug-discovery round to set beside this one.
The strongest case against that view comes from the three drugmakers on the partner list. Crypto Briefing wrote that they are betting Isomorphic's tools can speed discovery in ways their internal teams cannot match alone [25]. Their milestone payments arrive only if development goals are hit [23], and Johnson & Johnson's terms were not reported.
Alphabet has kept its majority [12] while outside investors bought into both priced rounds [4]. At $40 billion, a majority stake is worth more than $20 billion on paper [22]. Each higher-priced round lets Alphabet fund drug development without writing the whole check [4]. Isomorphic hopes the new money will speed its push to develop drugs [10]. The spending visible so far is new sites in the US and Switzerland [14].
The one-off reading fails if another AI drug-discovery company without human data raises at a similar step-up within the next year.
What to watch
- Final terms: whether the round closes between $40 billion and $50 billion, and who leads it.
- A first milestone payment from Eli Lilly or Novartis, or disclosure of the Johnson & Johnson deal terms.
Information, not investment advice. This story is general information about companies and markets, drawn from cited reporting. It is not a recommendation to buy, sell or hold any security; check the cited sources before acting.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence55
- Adoption25
- Hype gap+45
- Incentives55
- Confidence55
Perspective Coverage
6 publishers- Builder
- Builder 26%
- Operator
- Operator 17%
- Investor
- Investor 57%
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
Alphabet's Isomorphic Labs is reportedly in fundraising talks at a $40 billion valuation.
- [2]
Crypto Briefing, citing a Bloomberg report of October 8, 2026 based on sources, said Isomorphic is in early talks to raise at a valuation of at least $40 billion that could reach as much as $50 billion.
- [3]
The talks are preliminary and no deal has been finalized.
- [4]
Isomorphic closed a $2.1 billion Series B round in May 2026, five months before the talks, drawing Thrive Capital, Alphabet and the UK Sovereign AI Fund.
- [5]
The Series B followed a $600 million Series A in March 2025, which Thrive Capital led; Thrive also joined the Series B.
- [6]
Isomorphic has raised approximately $2.7 billion in disclosed external funding since its founding.
- [7]
Isomorphic Labs is led by Nobel Prize winner and former Google DeepMind CEO Demis Hassabis.
- [8]
Isomorphic was founded in 2021 as a spin-off of DeepMind; its core product is IsoDDE, the Isomorphic Drug Design Engine, which builds on AlphaFold, DeepMind's protein-structure prediction technology.
- [9]
Isomorphic has not released any clinical data and has not dosed any patients.
- [10]
The company hopes the new investment will accelerate its push to develop new drugs.
- [11]
Before these negotiations began, Isomorphic was valued at approximately $17.5 billion.
- [12]
Alphabet remains the majority owner of Isomorphic Labs.
- [13]
Isomorphic plans to start first-in-human trials by the end of 2026.
- [14]
Isomorphic has opened sites in the US and Switzerland as part of its expansion.
- [15]
Semafor reported fears that AI spending, on track to far exceed past investment booms, is creating a bubble that, were it to burst, would lead to "a far-reaching shock."
- [16]
Firms including DeepSeek, Moonshot and OpenAI are also chasing billions in fresh funding as they look to stay ahead in the global AI race.
- [17]
A $40 billion valuation is about 14.8 times Isomorphic's roughly $2.7 billion of disclosed external funding.
- [18]
A $50 billion valuation is about 18.5 times the roughly $2.7 billion of disclosed external funding.
- [19]
Moving from about $17.5 billion to $40 billion adds $22.5 billion of paper value, a roughly 2.3-fold step.
- [20]
The $2.1 billion Series B was 3.5 times the $600 million Series A, raised 14 months earlier.
- [21]
A $50 billion valuation would be about 2.9 times the prior mark of about $17.5 billion.
- [22]
At a $40 billion valuation, Alphabet's majority stake is worth more than $20 billion on paper.
- [23]
Isomorphic has partnerships with Eli Lilly, Novartis and Johnson & Johnson; the Eli Lilly and Novartis deals, announced in 2024, carry potential milestone payments of more than $3 billion combined, paid only if specified development goals are hit.
- [24]
The more than $3 billion in Lilly and Novartis potential milestones equals roughly 7.5% of a $40 billion valuation.
- [25]
Eli Lilly, Novartis and Johnson & Johnson are betting that Isomorphic's tools can speed up discovery in ways their internal teams cannot match alone.
Sources
5 independent publishers whose own reporting we read for this story.
- cityam.comGoogle DeepMind’s London AI drug spinout eyes $50bn valuation
1 article · October 8, 2026
- cryptobriefing.comIsomorphic Labs reportedly seeks funding at a valuation of at least $40 billion
1 article · October 7, 2026
- proactiveinvestors.comAlphabet's Isomorphic Labs seeks valuation of at least $40 billion in new funding round | NASDAQ:GOOG
1 article · October 8, 2026
- runtimewire.comIsomorphic Labs talks $40B valuation five months after $2.1B round
1 article · October 7, 2026
- semafor.comAlphabet’s biolab in funding talks at $40B valuation
1 article · October 8, 2026
- siliconangle.comAlphabet spinoff Isomorphic Labs reportedly raising funding at up to $50B valuation - SiliconANGLE
2 articles · October 8, 2026